SUNSHINE BIOPHARMA INC (SBFM)
US8677816014 - Common Stock
Taking everything into account, SBFM scores 4 out of 10 in our fundamental rating. SBFM was compared to 576 industry peers in the Biotechnology industry. SBFM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SBFM is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year SBFM has reported negative net income.
In the past year SBFM has reported a negative cash flow from operations.
In the past 5 years SBFM always reported negative net income.
In the past 5 years SBFM always reported negative operating cash flow.
1.2 Ratios
SBFM's Return On Assets of -12.81% is amongst the best of the industry. SBFM outperforms 86.91% of its industry peers.
Looking at the Return On Equity, with a value of -16.47%, SBFM belongs to the top of the industry, outperforming 88.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.81% | ||
| ROE | -16.47% | ||
| ROIC | N/A |
ROA(3y)-224.14%
ROA(5y)-526.54%
ROE(3y)-2003.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SBFM has a Gross Margin of 33.15%. This is in the better half of the industry: SBFM outperforms 76.96% of its industry peers.
In the last couple of years the Gross Margin of SBFM has declined.
The Profit Margin and Operating Margin are not available for SBFM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.86%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SBFM has been increased compared to 1 year ago.
SBFM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SBFM has an Altman-Z score of -0.98. This is a bad value and indicates that SBFM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.98, SBFM is in line with its industry, outperforming 56.89% of the companies in the same industry.
SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.98 |
ROIC/WACCN/A
WACC9.73%
2.3 Liquidity
SBFM has a Current Ratio of 4.41. This indicates that SBFM is financially healthy and has no problem in meeting its short term obligations.
SBFM has a Current ratio (4.41) which is comparable to the rest of the industry.
A Quick Ratio of 3.23 indicates that SBFM has no problem at all paying its short term obligations.
SBFM's Quick ratio of 3.23 is on the low side compared to the rest of the industry. SBFM is outperformed by 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.23 |
3. Growth
3.1 Past
SBFM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.24%, which is quite impressive.
Looking at the last year, SBFM shows a very strong growth in Revenue. The Revenue has grown by 193.30%.
The Revenue has been growing by 597.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)89.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.13%
Revenue 1Y (TTM)193.3%
Revenue growth 3Y597.5%
Revenue growth 5YN/A
Sales Q2Q%54.08%
3.2 Future
Based on estimates for the next years, SBFM will show a very strong growth in Earnings Per Share. The EPS will grow by 62.00% on average per year.
Based on estimates for the next years, SBFM will show a very strong growth in Revenue. The Revenue will grow by 110.76% on average per year.
EPS Next Y104.81%
EPS Next 2Y62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year97.23%
Revenue Next 2Y110.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
SBFM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 0.04 indicates a rather cheap valuation of SBFM.
100.00% of the companies in the same industry are more expensive than SBFM, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of SBFM to the average of the S&P500 Index (20.02), we can say SBFM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0.04 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SBFM's earnings are expected to grow with 62.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SBFM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SUNSHINE BIOPHARMA INC
NASDAQ:SBFM (7/1/2024, 7:00:02 PM)
After market: 0.3775 -0.03 (-6.3%)0.4029
-0.01 (-3.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.63M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0.04 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.81% | ||
| ROE | -16.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.15% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.23 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)89.24%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y104.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)193.3%
Revenue growth 3Y597.5%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y